Ionis Enters Global Licensing Deal with Recordati for Alexander Disease ASO Zilganersen: Secures $30M Upfront Payment to Accelerate International Expansion

July 5, 2026

Rare Disease Report USA

Overview

Ionis Pharmaceuticals has entered a global licensing agreement with Recordati for zilganersen, an antisense oligonucleotide (ASO) for Alexander disease, covering territories outside the U.S. Ionis will receive a $30 million upfront payment, with potential for future milestone payments and royalties based on sales. Zilganersen is designed to reduce GFAP protein levels, which abnormally accumulate in Alexander disease due to GFAP gene mutations.

In Depth

Key Findings

Ionis Pharmaceuticals has entered into a global licensing agreement with Recordati, an Italian pharmaceutical company, for zilganersen, a therapeutic for the ultra-rare and fatal neurological disorder, Alexander disease. This agreement covers territories outside the United States and aims to accelerate the international deployment of zilganersen, expanding access for a patient population with high unmet medical needs.

Technical/Clinical Details

Zilganersen is an antisense oligonucleotide (ASO) developed by Ionis Pharmaceuticals, designed to target the overexpression of glial fibrillary acidic protein (GFAP), which is the root cause of Alexander disease. Alexander disease is characterized by the abnormal accumulation of GFAP protein in astrocytes due to mutations in the GFAP gene, leading to severe neurological impairment. Zilganersen works by specifically binding to GFAP messenger RNA (mRNA), thereby inhibiting the translation of GFAP protein and reducing its levels. This mechanism holds the potential to slow disease progression and improve symptoms. Under the terms of the licensing agreement, Ionis will receive an upfront payment of $30 million from Recordati. Furthermore, Ionis retains the right to receive additional future payments based on the achievement of development, regulatory, and commercial milestones by Recordati for zilganersen. Ionis will also be eligible for royalties on zilganersen sales by Recordati outside the U.S. This agreement marks a critical step towards broadening global access to the drug for Alexander disease patients.

Background & Context

Alexander disease is a progressive neurodegenerative disorder, particularly aggressive in its infantile onset form, leading to rapid symptom deterioration and often premature death. Currently, there is no approved cure for Alexander disease, with treatment primarily focused on symptomatic relief, making the development of new therapeutics desperately needed by patients and their families. Ionis Pharmaceuticals is a pioneer in ASO technology, with a proven track record of developing and bringing multiple ASO drugs to market for rare neurological disorders. Recordati is a European pharmaceutical company with a strong focus on rare disease therapeutics, and the partnership combines the necessary expertise and resources for the global dissemination of zilganersen.

Strategic Significance & Outlook

The global licensing agreement between Ionis and Recordati is a significant commercial milestone for zilganersen to reach Alexander disease patients worldwide. While FDA approval is pending in the U.S. (refer to Article 14), if approved, Recordati will be responsible for sales and distribution in ex-U.S. markets, ensuring that more patients can access this potentially life-changing therapy. This agreement highlights the importance of international collaboration in rare disease drug development and may influence development and commercialization strategies for other rare neurological disorder therapeutics. Zilganersen’s success further reinforces the potential of the ASO modality to revolutionize the treatment of genetic neurological diseases, with its future international rollout and clinical outcomes being closely watched.

Source: https://globalgenes.org/raredaily/ionis-enters-global-licensing-deal-with-recordati-for-alexander-disease-aso/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.